Eupraxia Pharma (EPRX): Forecast Levels Chart

The stock price action on GURU.Markets for Eupraxia Pharmaceuticals (EPRX), which integrates eco-standards and bioethics into pharmaceutical development, is 16.14. Eupraxia Pharmaceuticals (EPRX) develops analgesics, competing against industry behemoths in this segment while facing risks from high testing costs and generic expansion. Simultaneously, the business is grappling with a liquidity shortage, depleting its reserves and raising investment to cover research and development expenses.

EPRX: Eupraxia Pharma Consensus Target 04/06/2024 - 11/12/2026

Analytical breakdowns for Eupraxia Pharmaceuticals (EPRX)

- current quotes and average value forecast:

Market Price eupraxiapharma.com|EPRX - Price Target Chart

- stock exchange capitalization data:

Market Valuation Eupraxia Pharma|EPRX - Total Company Value

- balance sheet net asset value indicators:

Accounting Value of a Share Eupraxia Pharmaceuticals|EPRX - Company Net Assets|Capitalization to Book Value Ratio eupraxiapharma.com|EPRX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital eupraxiapharma.com|EPRX - Company Aggregate Debts|Debts to Book Capitalization Eupraxia Pharma|EPRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Eupraxia Pharmaceuticals|Quick Liquidity Indicator eupraxiapharma.com

- earnings and valuation multiples information:

EPRX - Net Profit|Projected Future Earnings Eupraxia Pharmaceuticals|EPRX - Price to Earnings Ratio|Future Price to Earnings Multiple eupraxiapharma.com|EPRX - Price/Earnings to Growth Ratio|Company Value to EBITDA Eupraxia Pharma|EPRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Eupraxia Pharmaceuticals|EPRX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months eupraxiapharma.com|EPRX - Earnings growth in current year|Expected net earnings per share growth next year Eupraxia Pharmaceuticals

General company analysis:EPRX Eupraxia Pharmaceuticals, Inc.

Flagship merchandise of Eupraxia Pharmaceuticals Inc.

The long-term sustainability of Eupraxia Pharmaceuticals (EPRX) is determined by the market's ability to capitalize on DiffuSphere technology by reducing therapy side effects. The average target value on GURU.Markets, reflected in the analytical community's target history, measures the aggregated growth potential of the asset's value, allowing investors to compare fundamental valuation with the company's actual success in commercializing drugs for the management of postoperative pain.

Competitors of Eupraxia Pharmaceuticals